Abstract:Parkinson’s disease (PD) commences several years before the onset of motor features. Pathophysiological understanding of the pre-clinical or early prodromal stages of PD are essential for the development of new therapeutic strategies. Two categories of patients are ideal to study the early disease stages. Idiopathic rapid eye movement sleep behavior disorder (iRBD) represents a well-known prodromal stage of PD in which pathology is presumed to have reached the lower brainstem. The majority of patients with iRB… Show more
“…The decrease in the concentration of L-DOPA in plasma found in this study in patients at risk of developing PD can be due to the death of nigrostriatal dopaminergic neurons, which leads to a decrease in the synthesis of DA and L-DOPA. This is confirmed by a decrease in the concentration of L-DOPA and DA in the CFS [58], as well as by a decrease in the level of 18F-DOPA incorporation (positron emission tomography) into dopamine synthesis [51] and DAT binding (DAT scan) in nigrostriatal dopaminergic neurons in patients at risk of PD development [59].…”
Section: Plasma Monoamines and Their Metabolites In Patients At Riskmentioning
confidence: 73%
“…One of them is the search for biomarkers in body fluids in patients at risk of developing PD at the prodromal stage. These patients are selected for the presence of premotor symptoms, in the absence of motor symptoms [51]. Changes in body fluids found in patients at risk of developing PD, in contrast to those detected in untreated patients at an early clinical stage of PD, can be considered with certainty as candidates for diagnostic biomarkers of PD at the preclinical stage.…”
Section: Search For Blood Biomarkers In Patients At Risk Of Developin...mentioning